Spaarne Gasthuis Stichting — Clinical Trial Site

69 Registered trials

33 Currently recruiting

Organisation

Spaarne Gasthuis Stichting

Location

Hoofddorp, Netherlands

Identifier

ORG-100021671

Address

Spaarnepoort 1, 2134 TM, Netherlands

Departments

#2200 : oncology
#2200; oncology
2612:Cardiology
3708: Cardiology
Cardiology
Cardiology Department
Department of Oncology
Hemato-oncology
Hematology
Intensive Care
Internal Medicine
Internal Medicine / Oncology
Internal Medicine/Oncology
Interne geneeskunde
Kindergeneeskunde
Medical Oncology
N/A
NA
Neurology
Nucleaire geneeskunde
Oncologie
oncology
Oncology-Hematology
Pediatrics
Pulmonary Medicine
Spaarne Gasthuis
Spaarne Gasthuis, Haarlem Zuid
Spaarne ziekenhuis, dept. Internal medicine
Surgery

Clinical trials at this site (69)

Search interface

Laparoscopic Antibiotic Lavage to Prevent intra-abdominal Abscess formation in Complicated Appendicitis (ALPACA) Recruiting

2024-514850-59-00 Appendicitis 5 2025-02-24
BuLLSEYE Recruiting

2024-512950-13-00 Sepsis 11 2025-01-03
Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial Recruiting

2024-513092-40-00 Stroke 6 2024-12-05
DOSAgE study: A multicenter randomized phase III trial of DOSe-reduced Chemotherapy for Advanced Colorectal Cancer in Older patients Recruiting

2023-506115-17-00 Metastatic Colorectal Cancer 5 2024-10-14
Can we Save the rectum by watchful waiting or transanal surgery following short- or long-course radioTherapy and Additional local oR systemi… Recruiting

2024-514620-17-00 Patients with early-stage rectal cancer (defined as ear 4 2024-10-14
TAP-TAU Recruiting

2023-505430-10-00 Mild cognitive impairment and dementia 10 2024-10-10
HOVON 170 DLBCL: ANTICIPATE: Prevention of ANThracycline-Induced Cardiac dysfunction by dexrazoxane In PATients with diffusE large B-cell ly… Recruiting

2023-505377-32-00 Diffuse large B-cell lymphoma (DLBCL) 5 2024-08-15
CLEAR-PATH trial Recruiting

2024-513363-15-01 (Chronic) Peripheral (occlusive) arterial disease (PAD) 11 2024-07-22
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate… Recruiting

2024-511309-47-00 moderate thrombocytopenia 4 2024-07-17
A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch… Recruiting

2023-504899-25-00 Metastatic castration resistant prostate cancer 5 2024-04-04
A phase 2 trial in stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab - TURANDORELA Recruiting

2023-507460-39-00 Adult patients with resectable muscle-invasive urotheli 10 2024-02-15
Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-vol… Recruiting

2023-506698-36-00 low-volume metastatic castration-sensitive prostate can 5 2024-02-02
Prevention of opioid-induced constipation in patients with advanced cancer. Recruiting

2023-509462-38-00 Patients with advanced cancer. 11 2022-10-25
The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: a randomized multi-center study in resectable HER2… Recruiting

2024-513797-22-00 HER2 positive esophageal adenocarcinoma 5 2022-03-09
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer - the NICHE trial Recruiting

2024-513314-35-00 Adenocarcinoma of the Colon or rectosigmoid (considered 4 2017-01-20
DRUP trial Recruiting

2023-509152-33-00 Advanced solid tumor 4 2016-07-25
A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxeta… Ended

2024-520155-24-00 Metastatic castration resistant prostate cancer (mCRPC) 4 2025-10-16
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women with Breast Cancer Who Are Having Hormone Therapy Ended

2024-510719-31-00 Moderate to Severe Vasomotor Symptoms (VMS) 5 2025-01-24
Prevention of the return of nephrotic syndrom in children by adding levamisole to prednisolone treatment Ended

2024-517467-23-00 steroid sensitive idiopathic nephrotic syndrome 5 2024-11-29
First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in… Ended

2022-502808-72-00 Chronic Lymphocytic Leukemia 4 2024-09-11
Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS) Ended

2024-513105-31-00 Multiple Sclerosis 6 2024-07-30
DUTCH-WAIST Ended

2022-501392-81-00 Obesity 6 2024-07-25
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25